Molecular signatures of vaccine adjuvants

Vaccine

Volumn 33, Issue 40, 2015, Pages 5302-5307

  Olafsdottir, Thorunn ^a   Lindqvist, Madelene ^a   Harandi, Ali M ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Mode of action of adjuvants; Omics; Systems biology; Vaccine adjuvants

Indexed keywords

IMMUNOLOGICAL ADJUVANT; VACCINE; TRANSCRIPTOME;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ARTICLE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; DRUG MECHANISM; DRUG POTENCY; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TECHNIQUE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; VACCINATION; ANIMAL; CELLULAR IMMUNITY; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; STATISTICAL ANALYSIS; SYSTEMS BIOLOGY;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; ANIMALS; DATA INTERPRETATION, STATISTICAL; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, INNATE; SYSTEMS BIOLOGY; TRANSCRIPTOME; VACCINATION; VACCINES;

EID: 84941803825     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.04.099     Document Type: Article

References (54)

1. Querec T.D., et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009, 10(1):116-125.
2. Li S., et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat. Immunol. 2014, 15(2):195-204.
3. Caproni E., et al. MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I-independent mechanism of action. J Immunol 2012, 188(7):3088-3098.
4. Seok J., et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2013, 110(9):3507-3512.
5. Takao K., Miyakawa T. Genomic responses in mouse models greatly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2014, 112(4):1167-1172.
6. Kool M., Fierens K., Lambrecht B.N. Alum adjuvant: some of the tricks of the oldest adjuvant. J Med Microbiol 2012, 61(7):927-934.
7. Reed S.G., Orr M.T., Fox C.B. Key roles of adjuvants in modern vaccines. Nat Med 2013, 19(12):1597-1608.
8. Franchi L., Nunez G. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur J Immunol 2008, 38(8):2085-2089.
9. Li H., et al. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol 2008, 181(1):17-21.
10. O'Hagan D.T., et al. The mechanism of action of MF59-an innately attractive adjuvant formulation. Vaccine 2012, 30(29):4341-4348.
11. Khurana S., et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med 2011, 3(85). p. 85ra48.
12. Calabro S., et al. The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. Vaccine 2013, 31(33):3363-3369.
13. Mosca F., et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci USA 2008, 105(30):10501-10506.
14. Garcon N., Vaughn D.W., Didierlaurent A.M. Development and evaluation of AS03, an Adjuvant System containing alpha-tocopherol and squalene in an oil-in-water emulsion. Expert Rev Vaccines 2012, 11(3):349-366.
15. Garcon N., et al. Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach. BioDrugs 2011, 25(4):217-226.
16. Garcon N., Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 2011, 10(4):471-486.
17. Garcon N., Wettendorff M., Van Mechelen M. Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile. Expert Opin Biol Ther 2011, 11(5):667-677.
18. Morel S., et al. Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011, 29(13):2461-2473.
19. Didierlaurent A.M., et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009, 183(10):6186-6197.
20. Duthie M.S., et al. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 2011, 239(1):178-196.
21. Steinhagen F., et al. TLR-based immune adjuvants. Vaccine 2011, 29(17):3341-3355.
22. Lahiri A., Das P., Chakravortty D. Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond. Vaccine 2008, 26(52):6777-6783.
23. Kaisho T., Akira S. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 2002, 1589(1):1-13.
24. Bode C., et al. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2011, 10(4):499-511.
25. Klaschik S., Tross D., Klinman D.M. Inductive and suppressive networks regulate TLR9-dependent gene expression in vivo. J Leukoc Biol 2009, 85(5):788-795.
26. Mestas J., Hughes C.C. Of mice and not men: differences between mouse and human immunology. J Immunol 2004, 172(5):2731-2738.
27. Kwissa M., et al. Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates. Blood 2012, 119(9):2044-2055.
28. Orr M.T., et al. MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant. Eur J Immunol 2013, 43(9):2398-2408.
29. Lambert S.L., et al. Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant glucopyranosyl Lipid A. PLoS ONE 2012, 7(12):pe51618.
30. Baldwin S.L., et al. Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 2009, 27(43):5956-5963.
31. Lindqvist M., et al. Unraveling molecular signatures of immunostimulatory adjuvants in the female genital tract through systems biology. PLoS ONE 2011, 6(6):pe20448.
32. Tengvall S., et al. Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes. J Virol 2006, 80(11):5283-5291.
33. Lindqvist M., et al. The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection. J Immunol 2009, 182(10):6435-6443.
34. Lindqvist M., et al. Local cytokine and inflammatory responses to candidate vaginal adjuvants in mice. Vaccine 2009, 28(1):270-278.
35. Brown K.E., et al. Role of PD-1 in regulating acute infections. Curr Opin Immunol 2010, 22(3):397-401.
36. Rappuoli R., et al. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol Today 1999, 20(11):493-499.
37. Tritto E., et al. The acquired immune response to the mucosal adjuvant LTK63 imprints the mouse lung with a protective signature. J Immunol 2007, 179(8):5346-5357.
38. Lewis D.J., et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS ONE 2009, 4(9):pe6999.
39. Wu T.Y., et al. Rational design of small molecules as vaccine adjuvants. Sci Transl Med 2014, 6(263). p. 263ra160.
40. Zhao S., et al. Comparison of RNA-Seq and microarray in transcriptome profiling of activated T cells. PLoS ONE 2014, 9(1):pe78644.
41. Nakaya H.I., Li S., Pulendran B. Systems vaccinology: learning to compute the behavior of vaccine induced immunity. Wiley Interdiscip Rev Syst Biol Med 2012, 4(2):193-205.
42. Wishart D.S. Current progress in computational metabolomics. Brief Bioinform 2007, 8(5):279-293.
43. Patti G.J., Yanes O., Siuzdak G. Innovation: Metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol 2012, 13(4):263-269.
44. Saric J. Interactions between immunity and metabolism-contributions from the metabolic profiling of parasite-rodent models. Parasitology 2010, 137(9):1451-1466.
45. Shin J.H., et al. (1)H NMR-based metabolomic profiling in mice infected with Mycobacterium tuberculosis. J Proteome Res 2011, 10(5):2238-2247.
46. Weiner J., et al. Biomarkers of inflammation, immunosuppression and stress with active disease are revealed by metabolomic profiling of tuberculosis patients. PLoS ONE 2012, 7(7). pe40221.
47. O'Sullivan A., et al. Metabolomics of cerebrospinal fluid from humans treated for rabies. J Proteome Res 2013, 12(1):481-490.
48. Yang F., et al. DNA immunization perturbs lipid metabolites and increases risk of atherogenesis. J Proteome Res 2008, 7(2):741-748.
49. Harandi A.M., Medaglini D., Shattock R.J. Vaccine adjuvants: a priority for vaccine research. Vaccine 2010, 28(12):2363-2366.
50. Haining W.N., Pulendran B. Identifying gnostic predictors of the vaccine response. Curr Opin Immunol 2012, 24(3):332-336.
51. Boehm J.S., Hahn W.C. Towards systematic functional characterization of cancer genomes. Nat Rev Genet 2011, 12(7):487-498.
52. Cong L., et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013, 339(6121):819-823.
53. Bendall S.C., et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 2011, 332(6030):687-696.
54. Flatz L., et al. Single-cell gene-expression profiling reveals qualitatively distinct CD8 T cells elicited by different gene-based vaccines. Proc Natl Acad Sci USA 2011, 108(14):5724-5729.